Press Releases

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research...

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN®, "eribulin") will be presented during the 2022 San Antonio...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will have a total of 34 posters, including the latest data on its in-house discovered and...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's Phase 3 confirmatory Clarity AD clinical trial for...

Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022 /PRNewswire/ -- Eisai today announced final...

ALL KEY SECONDARY ENDPOINTS ALSO MET, DEMONSTRATING HIGHLY STATISTICALLY SIGNIFICANT RESULTS PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) INCIDENCE WAS WITHIN EXPECTATIONS EISAI AIMS TO...

RAHWAY, N.J. and NUTLEY, N.J., Sept. 10, 2022 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the...

Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Studies (Presentation: #259P) NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results...